Novartis AG Shares Outstanding 2010-2024 | NVS
Novartis AG shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Novartis AG shares outstanding for the quarter ending September 30, 2024 were 2.027B, a 2.31% decline year-over-year.
- Novartis AG 2023 shares outstanding were 2.092B, a 4.78% decline from 2022.
- Novartis AG 2022 shares outstanding were 2.197B, a 2.79% decline from 2021.
- Novartis AG 2021 shares outstanding were 2.26B, a 1.57% decline from 2020.
Novartis AG Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
2,092 |
| 2022 |
2,197 |
| 2021 |
2,260 |
| 2020 |
2,296 |
| 2019 |
2,319 |
| 2018 |
2,344 |
| 2017 |
2,371 |
| 2016 |
2,400 |
| 2015 |
2,438 |
| 2014 |
2,426 |
| 2013 |
2,479 |
| 2012 |
2,445 |
| 2011 |
2,413 |
| 2010 |
2,301 |
| 2009 |
2,277 |
Novartis AG Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
2,027 |
| 2024-06-30 |
2,046 |
| 2024-03-31 |
2,056 |
| 2023-12-31 |
2,092 |
| 2023-09-30 |
2,075 |
| 2023-06-30 |
2,095 |
| 2023-03-31 |
2,120 |
| 2022-12-31 |
2,197 |
| 2022-09-30 |
2,180 |
| 2022-06-30 |
2,211 |
| 2022-03-31 |
2,237 |
| 2021-12-31 |
2,260 |
| 2021-09-30 |
2,254 |
| 2021-06-30 |
2,258 |
| 2021-03-31 |
2,265 |
| 2020-12-31 |
2,296 |
| 2020-09-30 |
2,302 |
| 2020-06-30 |
2,304 |
| 2020-03-31 |
2,292 |
| 2019-12-31 |
2,319 |
| 2019-09-30 |
2,297 |
| 2019-06-30 |
2,333 |
| 2019-03-31 |
2,339 |
| 2018-12-31 |
2,344 |
| 2018-09-30 |
2,338 |
| 2018-06-30 |
2,346 |
| 2018-03-31 |
2,347 |
| 2017-12-31 |
-1,186 |
| 2017-09-30 |
2,359 |
| 2017-06-30 |
2,373 |
| 2017-03-31 |
2,389 |
| 2016-12-31 |
-1,200 |
| 2016-09-30 |
2,401 |
| 2016-06-30 |
2,401 |
| 2016-03-31 |
2,398 |
| 2015-12-31 |
2,403 |
| 2015-09-30 |
2,438 |
| 2015-06-30 |
2,451 |
| 2015-03-31 |
2,446 |
| 2014-12-31 |
2,426 |
| 2014-09-30 |
2,460 |
| 2014-06-30 |
2,471 |
| 2014-03-31 |
2,479 |
| 2013-12-31 |
2,479 |
| 2013-09-30 |
2,480 |
| 2013-06-30 |
2,490 |
| 2013-03-31 |
2,473 |
| 2012-12-31 |
2,445 |
| 2012-09-30 |
2,445 |
| 2012-06-30 |
2,441 |
| 2012-03-31 |
2,435 |
| 2011-12-31 |
2,413 |
| 2011-09-30 |
2,450 |
| 2011-06-30 |
2,426 |
| 2011-03-31 |
2,305 |
| 2010-12-31 |
2,301 |
| 2010-09-30 |
2,300 |
| 2010-06-30 |
2,297 |
| 2010-03-31 |
2,290 |
| 2009-12-31 |
2,277 |
| 2009-09-30 |
2,285 |
| 2009-06-30 |
2,280 |
| 2009-03-31 |
2,283 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$211.084B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
